Lipoxins: Endogenous regulators of inflammation

Blaithin McMahon, Catherine Godson

Research output: Contribution to journalReview articlepeer-review

106 Scopus citations


Over the past decade, compelling in vivo and in vitro studies have highlighted lipoxins (LXs) and aspirin-triggered LXs (ATLs) as endogenously produced anti-inflammatory eicosanoids. LXs and ATLs elicit distinct anti-inflammatory and proresolution bioactions that include inhibition of leukocyte-mediated injury, stimulation of macrophage clearance of apoptotic neutrophils, repression of proinflammatory cytokine production, modulation of cytokine-stimulated metalloproteinase activity, and inhibition of cell proliferation and migration. An overview of recent advances in LX physiology is provided, with particular emphasis on the cellular and molecular processes involved. These data coupled with in vivo models of inflammatory diseases suggest that LX bioactions may be amenable to pharmacological mimicry for therapeutic gain.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Issue number2 55-2
StatePublished - Feb 2004
Externally publishedYes


  • Lipoxin A receptor
  • Mesangial and tubular epithelial cells

ASJC Scopus subject areas

  • Physiology


Dive into the research topics of 'Lipoxins: Endogenous regulators of inflammation'. Together they form a unique fingerprint.

Cite this